维康药业(300878) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥132,259,899.28, representing a 7.74% increase compared to ¥122,754,754.51 in the same period last year[7] - Net profit attributable to shareholders was ¥20,272,669.37, up 28.86% from ¥15,732,140.29 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥19,671,120.10, reflecting a 26.09% increase from ¥15,601,124.90 in the previous year[7] - Basic earnings per share decreased by 3.37% to ¥0.2520 from ¥0.2608 year-on-year[7] - Total operating revenue for Q1 2021 was CNY 132,259,899.28, an increase from CNY 122,754,754.51 in the previous period[53] - Net profit for Q1 2021 reached CNY 20,371,610.56, representing a 29.5% increase from CNY 15,732,140.29 in Q1 2020[55] - Operating profit for Q1 2021 was CNY 23,685,671.98, up 24.0% from CNY 19,036,151.28 in the previous year[55] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,004,162.70, a significant decline of 2937.93% compared to -¥1,481,406.73 in the same period last year[7] - Cash flow from operating activities for Q1 2021 was CNY 134,001,330.89, an increase from CNY 119,173,835.10 in the same period last year[62] - The company reported a total cash outflow of 182,501,552.16 CNY from operating activities, which is a 43% increase compared to the previous period[63] - The ending balance of cash and cash equivalents was 484,957,165.65 CNY, down from 593,975,811.41 CNY at the beginning of the period[64] - The company experienced a net decrease in cash and cash equivalents of 109,018,645.76 CNY during the period[64] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,612,680,869.75, a decrease of 0.99% from ¥1,628,782,391.06 at the end of the previous year[7] - Total liabilities decreased to CNY 170,676,977.62 from CNY 207,952,826.21 in the previous period[51] - Current liabilities were CNY 127,641,978.57, down from CNY 177,209,223.49 in the previous period[51] - Total current assets decreased to ¥945.20 million from ¥998.62 million, reflecting a decline of about 5.3%[45] - The total current liabilities increased from CNY 177,209,223.49 to CNY 213,650,314.37, indicating a rise in short-term financial obligations[73] Shareholder Information - The company reported a total of 15,486 common shareholders at the end of the reporting period[11] - The largest shareholder, Liu Zhongliang, holds 60.82% of the shares, totaling 48,921,389 shares[11] - The total equity attributable to shareholders reached CNY 1,456,966,924.27, compared to CNY 1,439,473,664.76 in the previous period[51] Operational Highlights - The company is executing its annual business plan smoothly, with all operations proceeding in an orderly manner[24] - The company faces policy risks due to ongoing national healthcare reforms, which could impact operations if not addressed timely[25] - The company has established a comprehensive quality management system to mitigate risks associated with product quality control[27] - The company is developing generic drug projects and secondary development of key products, which require lower investment and shorter R&D cycles[28] Research and Development - R&D expenses decreased by 30.66% to 4.09 million yuan, attributed to reduced external R&D costs[18] - Research and development expenses for Q1 2021 totaled CNY 4,091,733.61, a decrease of 30.6% from CNY 5,900,941.97 in Q1 2020[55] Investment and Capital Expenditure - The company approved an additional investment of ¥97.21 million in the pharmaceutical health industry park project, increasing the total planned investment to ¥358.62 million[36] - The company has a total of CNY 745,116,281.86 in capital reserves, indicating strong financial backing[71] Risk Management - Management risks are anticipated due to rapid expansion, prompting the company to enhance training for existing management personnel and recruit new staff[29] - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[39] - There were no significant changes in the feasibility of investment projects during the reporting period[36]